Core Insights - Immutep Limited has received a cash payment of €2,588,954 (~ A$4,567,769) from the French Government under the Crédit d'Impôt Recherche (CIR) scheme, which supports R&D activities [1][3] - The CIR allows French companies to be reimbursed 30% of their eligible R&D expenditures, benefiting Immutep through its subsidiary in France [2][3] - The funds will be allocated to the global clinical development of Immutep's products, specifically eftilagimod alfa and IMP761 [4] Company Overview - Immutep is a late-stage biotechnology company focused on developing immunotherapies for cancer and autoimmune diseases, particularly leveraging LAG-3 therapeutics [5] - The company aims to provide innovative treatment options and maximize shareholder value through its diversified product portfolio [5]